Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Morris

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Genetic Epidemiology|December 6, 2016
Genome-wide survey in African Americans demonstrates potential epistasis of fitness in the human genomeHeming Wang, Yoonha Choi, Bamidele Tayo, et al.
Future Oncology (London, England)|November 5, 2016
Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic reviewAtallah Baydoun, Bryan Traughber, Nathan Morris, et al.
Clinical Pharmacology and Therapeutics|December 15, 2017
Pharmacologic Targeting of Red Blood Cells to Improve Tissue OxygenationJames D Reynolds, Trevor Jenkins, Faisal Matto, et al.
BMJ Open Gastroenterology|March 31, 2023
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitisMarla C Dubinsky, Vipul Jairath, Brian G Feagan, et al.
Intestinal Research|May 9, 2024
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studiesTaku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.
Journal of Crohn'S & Colitis|June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial resultsVipul Jairath, Fernando Magro, Marijana Protic, et al.
Crohn'S & Colitis 360|February 13, 2023
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease RegistryRaymond K Cross, April N Naegeli, Ryan W Harrison, et al.
Journal of Crohn'S & Colitis|November 2, 2022
Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental ColitisMeghali Nighot, Pei-Luan Liao, Nathan Morris, et al.
Crohn'S & Colitis 360|March 30, 2026
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY studyVipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Genetic Epidemiology|December 6, 2016
Genome-wide survey in African Americans demonstrates potential epistasis of fitness in the human genomeHeming Wang, Yoonha Choi, Bamidele Tayo, et al.
Future Oncology (London, England)|November 5, 2016
Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic reviewAtallah Baydoun, Bryan Traughber, Nathan Morris, et al.
Clinical Pharmacology and Therapeutics|December 15, 2017
Pharmacologic Targeting of Red Blood Cells to Improve Tissue OxygenationJames D Reynolds, Trevor Jenkins, Faisal Matto, et al.
BMJ Open Gastroenterology|March 31, 2023
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitisMarla C Dubinsky, Vipul Jairath, Brian G Feagan, et al.
Intestinal Research|May 9, 2024
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studiesTaku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.
Journal of Crohn'S & Colitis|June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial resultsVipul Jairath, Fernando Magro, Marijana Protic, et al.
Crohn'S & Colitis 360|February 13, 2023
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease RegistryRaymond K Cross, April N Naegeli, Ryan W Harrison, et al.
Journal of Crohn'S & Colitis|November 2, 2022
Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental ColitisMeghali Nighot, Pei-Luan Liao, Nathan Morris, et al.
Crohn'S & Colitis 360|March 30, 2026
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY studyVipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
Pageof 6